Affordable Access

deepdyve-link
Publisher Website

Oncological Follow-up with 2-[ 18F]-FDG PET/CT in Li-Fraumeni Syndrome

Authors
  • Hernandez, Marylin Acuña1
  • Vega Gonzalez, Iván Fabricio2
  • Vélez, Lina López2
  • Arango, Catalina Melo3
  • 1 Autonomous University of Bucaramanga (UNAB), Department of Nuclear Medicine, Bucaramanga, Santander, Colombia
  • 2 , Antioquia, Colombia
  • 3 Las Américas Clinic Auna, Department of Radiology, Medellin, Antioquia, Colombia
Type
Published Article
Journal
Molecular Imaging and Radionuclide Therapy
Publisher
Galenos Publishing
Publication Date
Jun 03, 2021
Volume
30
Issue
2
Pages
110–112
Identifiers
DOI: 10.4274/mirt.galenos.2020.33255
PMID: 34082513
PMCID: PMC8185483
Source
PubMed Central
Keywords
Disciplines
  • Interesting Image
License
Unknown

Abstract

Li-Fraumeni syndrome is a rare disorder caused by abnormalities of the tumor-suppressor protein P53 gene. We present the case of a 26-years-old female diagnosed with bilateral ductal carcinoma. The genetic panel for breast cancer gene 1 (BRCA1) and BRCA2 mutations was negative and positive heterozygous germline tumor protein P53 gene mutations, considering Li-Fraumeni syndrome. A 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) was used for postsurgical staging to show the right lung hypermetabolic nodule. A lobectomy was accomplished, and histopathology reported pulmonary adenocarcinoma. A year later, oncological follow-up was conducted with 2-[18F]-FDG PET/CT without evidence of abnormalities.

Report this publication

Statistics

Seen <100 times